论文部分内容阅读
目的:探讨参麦注射液对脓毒症患者血清炎症介质释放的影响。方法:将60例符合脓毒症诊断标准的急诊危重病患者,排除恶性肿瘤,妊娠患者,随机分为参麦组(30例)和对照组(30例),两组患者资料具有可比性。在相同基础治疗条件下,参麦组增加参麦注射液50mL静滴,12h1次,连续用7天。分别于治疗前、治疗第3天和第7天抽取外周静脉血,用酶联免疫吸附法(ELISA)检测患者血清肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、IL-6、IL-8和IL-10水平,并记录急性生理学与慢性健康状况评分系统Ⅱ(APACHEⅡ)评分。结果:与对照组比较,加用参麦注射液治疗后不同时间点血清TNF-α、IL-1β、IL-6、IL-8和IL-10水平及A-PACHEⅡ均明显降低,差异具有统计学意义(P<0.05或P<0.01)。结论:参麦注射液可降低脓毒症患者的血清TNF-α、IL-1β、IL-6、IL-8和IL-10水平,抑制过度的炎症反应,调节患者免疫功能,改善预后。
Objective: To investigate the effect of Shenmai injection on the release of serum inflammatory mediators in patients with sepsis. Methods: Sixty critically ill patients with critical illness who were diagnosed as sepsis, excluding malignant tumors and pregnant women were randomly divided into two groups: control group (30 cases) and control group (30 cases). The data of two groups were comparable. Under the same basic treatment conditions, Shenmai injection of Shenmai injection increased 50mL intravenous infusion, 12h1 times, continuous with 7 days. Peripheral venous blood was collected before treatment, on the 3rd and 7th day of treatment, respectively. Serum levels of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were detected by enzyme-linked immunosorbent assay (ELISA) ), IL-6, IL-8 and IL-10 levels were recorded and the APACHE II score was recorded. Results: Compared with the control group, the levels of TNF-α, IL-1β, IL-6, IL-8 and IL-10 and A-PACHEⅡ were significantly decreased at different time points after treatment with Shenmai injection Significance (P <0.05 or P <0.01). Conclusion: Shenmai injection can reduce the serum levels of TNF-α, IL-1β, IL-6, IL-8 and IL-10 in sepsis patients, inhibit excessive inflammatory reaction, regulate immune function and improve prognosis.